Unknown

Dataset Information

0

Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.


ABSTRACT: MYC rearrangements usually confer aggressive biological behavior to large B-cell lymphomas. In this study, we aimed to evaluate the relevance of LMO2 detection to the clinical approach to these tumors. First, the ability of LMO2 loss of expression to recognize the presence of MYC rearrangements was evaluated. A series of 365 samples obtained from 351 patients, including 28 Burkitt lymphoma, 230 diffuse large B-cell lymphoma, 30 high-grade B-cell lymphoma with MYC and BCL2/BCL6 rearrangements, eight high-grade B-cell lymphoma-NOS, 43 transformed diffuse large B-cell lymphoma, and 26 high-grade follicular lymphomas was analyzed. Among the CD10-positive tumors prospectively analyzed in whole tissue sections, LMO2 negative expression obtained values of 88% sensitivity, 94% specificity, and 93% accuracy, proving the utility of LMO2 to screen MYC rearrangements. In addition, survival analyses were performed in a series of 155 patients. As per univariate analyses, the prognosis relevance of LMO2 was as useful as that of the diagnostic categories, MYC rearrangements, and MYC immunohistochemistry. Multivariate models revealed that both LMO2 (hazard ratio 0.51 p = 0.02) and IPI (hazard ratio 1.67 p < 0.005) were independent variables predicting overall survival. Finally, MYC and LMO2 mRNA expression were analyzed in a small group of cases. Taken together, these findings show the interest of LMO2 testing in large B-cell lymphomas.

SUBMITTER: Vazquez I 

PROVIDER: S-EPMC7226002 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2011-01-01 | S-EPMC3158840 | BioStudies
2020-01-01 | S-EPMC7596913 | BioStudies
1000-01-01 | S-EPMC6199666 | BioStudies
2019-01-01 | S-EPMC6752209 | BioStudies
2018-01-01 | S-EPMC6278976 | BioStudies
2012-01-01 | S-EPMC3369683 | BioStudies
1000-01-01 | S-EPMC4823044 | BioStudies
2019-01-01 | S-EPMC6717587 | BioStudies
2016-01-01 | S-EPMC4925176 | BioStudies
2020-01-01 | S-EPMC7192846 | BioStudies